ResultsIQ

ResultsIQ › Latest results › IOL Chemicals and Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited Q2 FY26 results press release summary

NSE: IOLCP · BSE: 524164

Results press release of 11 Nov 2025, summarised by AI from the filing.

IOLCP Q2 FY26 revenue ₹567.5 cr, EBITDA ₹64.0 cr and PAT ₹30.0 cr, with margin expansion and Pantoprazole CEP received.

Key takeaways

  1. Guidance No forward guidance was given in the release.
  2. Sequential change PAT marginally impacted sequentially by higher fuel costs after Punjab floods disrupted supply chains.
  3. Growth driver Pharmaceuticals segment momentum led by strong traction in non-Ibuprofen APIs.
  4. Main risk Chemicals pricing remains under pressure even as volumes recover.

Original filing on BSE

IOL Chemicals and Pharmaceuticals Limited Q1 FY27 results

As filed: Revenue ₹756 cr (+37% year on year), EBITDA ₹103 cr (+64% year on year), PAT ₹64.4 cr (+89% year on year), EBITDA margin 13.7% (+227 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹619 cr (+17% year on year), EBITDA ₹92.5 cr (+47% year on year), PAT ₹53.2 cr (+71% year on year), EBITDA margin 14.9% (+300 bps). Score 85 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 300 bps year on year. Profit rose ₹22.2 cr on a year ago, more than the ₹3.0 cr it added the year before. Share price after the results: +18.2% in 30 days (Nifty 500: +2.8%).
  • Q3 FY26: Revenue ₹580 cr (+11% year on year), EBITDA ₹57.3 cr (+22% year on year), PAT ₹20.6 cr (+38% year on year), EBITDA margin 9.9% (+88 bps). Score 72 of 100, Above trend. Revenue and profit before exceptional items growth were well above the company's own trend; EBITDA growth was above it. EBITDA margin rose 88 bps year on year. Profit fell 3% from last quarter. Share price after the results: −15.0% in 30 days (Nifty 500: −9.9%).
  • Q2 FY26: Revenue ₹568 cr (+8% year on year), EBITDA ₹56.0 cr (+33% year on year), PAT ₹30.0 cr (+58% year on year), EBITDA margin 9.9% (+187 bps). Score 77 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 187 bps year on year. Profit fell 12% from last quarter. Share price after the results: −5.4% in 30 days (Nifty 500: −0.6%).
  • Q1 FY26: Revenue ₹552 cr (+10% year on year), EBITDA ₹63.0 cr (+21% year on year), PAT ₹34.0 cr (+13% year on year), EBITDA margin 11.4% (+105 bps). Score 71 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were above it. EBITDA margin rose 105 bps year on year. Share price after the results: +1.9% in 29 days (Nifty 500: +0.7%).
  • Q4 FY25: Revenue ₹528 cr (+5% year on year), EBITDA ₹63.0 cr (+31% year on year), PAT ₹31.0 cr (+11% year on year), EBITDA margin 11.9% (+241 bps). Score 71 of 100, Above trend. Revenue and profit growth were above the company's own trend; EBITDA growth was well above it. EBITDA margin rose 241 bps year on year. Share price after the results: +10.6% in 28 days (Nifty 500: +0.2%).
  • Q3 FY25: Revenue ₹523 cr (+1% year on year), EBITDA ₹47.0 cr (+7% year on year), PAT ₹21.0 cr (−9% year on year), EBITDA margin 9.0% (+53 bps). Score 55 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA growth was above it; profit growth was below it. EBITDA margin rose 53 bps year on year.
  • Q2 FY25: Revenue ₹526 cr (−3% year on year), EBITDA ₹42.0 cr (−34% year on year), PAT ₹19.0 cr (−50% year on year), EBITDA margin 8.0% (−376 bps). Score 10 of 100, Below trend. EBITDA margin fell 376 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 37% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

IOL Chemicals and Pharmaceuticals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.